CD19 and mantle cell lymphoma: Also, the killing of MCL cells by anti-CD19 CAR T-cells was significantly augmented in the presence of ibrutinib, suggesting an additive cytotoxic effect of the combination of both ibrutinib-sensitive (MCL-RL) and -resistant (JEKO-1) MCL cells.